反应详情

4-chloro-N-({4-chloro-3-[(3-cyano-5-formylphenyl)oxy]-2-fluorophenyl}methyl)-1-({[2-(trimethylsilyl)ethyl]oxy}methyl)-1H-imidazole-5-carboxamide (40 mg, 0.071 mmol) and morpholine (6.18 mg, 0.071 mmol) were mixed in 1,2-dichloroethane (2 mL) and treated with sodium triacetoxyborohydride (21 mg, 0.099 mmol) and acetic acid (4.06 μl, 0.071 mmol). The mixture was stirred at RT for 1 h then TFA (2 ml, 26.0 mmol) was added to the solution and stirred for 30 min. The solvent was removed under vacuum and the crude product was purified by Reverse Phase HPLC (MeCN/water 0.1% formic acid) to give 30 mg (84%) of the title compound as a white solid. 1H NMR (400 MHz, methanol-d4) δ ppm 8.08 (s, 1H), 7.61-7.81 (m, 1H), 7.46 (s, 1H), 7.29-7.41 (m, 2H), 7.24 (s, 1H), 7.08-7.19 (m, 1H), 4.63 (s, 2H), 3.52-3.84 (m, 4H), 2.53 (m., 4H). LC-MS (ES+) m/z 502.9 [M+1].

1. stirringstirred for 30 min
2. customThe solvent was removed under vacuum
3. customthe crude product was purified by Reverse Phase HPLC (MeCN/water 0.1% formic acid)